Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 14, 2022, Mr. Douglas J. Swirsky provided notice of his resignation
from the Board of Directors (the "Board") of NeuroBo Pharmaceuticals, Inc. (the
"Company"), effective immediately. Mr. Swirsky's resignation was not the result
of any disagreement with the Company regarding the Company's operations,
policies or practices.
Andrew I. Koven, a current director of the Company was elected Chairman of the
Board and Michael Salsbury, a current director of the Company was appointed to
the Audit Committee of the Board and appointed Chairman of the Audit Committee.
As a result, the Audit Committee of the Board currently consists of Jason
Groves, Andrew I. Koven, Michael Salsbury.
The Board has determined that each of Mr. Groves, Mr. Koven and Mr. Salsbury are
independent in accordance with the listing standards of Nasdaq and the Company's
internal policies, and that each otherwise meets all applicable requirements to
serve on the Audit Committee, including the rules and regulations of the
Securities and Exchange Commission (the "SEC").
© Edgar Online, source Glimpses
NEUROBO PHARMACEUTICALS, INC. 
